These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 9139464

  • 21. Replacement therapy with imiglucerase for type 1 Gaucher's disease.
    Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, Bar-Ziv Y, Foldes J, Schwartz AJ, Abrahamov A.
    Lancet; 1995 Jun 10; 345(8963):1479-80. PubMed ID: 7769903
    [Abstract] [Full Text] [Related]

  • 22. Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase.
    Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, Rosen BR, Baker J, Niklason LT, Hill SC.
    Pediatrics; 1995 Oct 10; 96(4 Pt 1):629-37. PubMed ID: 7567322
    [Abstract] [Full Text] [Related]

  • 23. [Enzyme replacement therapy in type 1 Gaucher's disease].
    Aggio MC, Fernández V, Marcilese M.
    Medicina (B Aires); 1994 Oct 10; 54(2):140-4. PubMed ID: 7997130
    [Abstract] [Full Text] [Related]

  • 24. Gaucher's disease in Lithuania: its diagnosis and treatment.
    Kleinotienė G, Tylki-Szymanska A, Czartoryska B.
    Medicina (Kaunas); 2011 Oct 10; 47(7):405-11. PubMed ID: 22112991
    [Abstract] [Full Text] [Related]

  • 25. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease.
    Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO.
    Proc Natl Acad Sci U S A; 1990 Mar 10; 87(5):1913-6. PubMed ID: 2308952
    [Abstract] [Full Text] [Related]

  • 26. Recombinant macrophage targeted enzyme replacement therapy for Gaucher disease in India.
    Nagral A, Mewawalla P, Jagadeesh S, Kabra M, Phadke SR, Verma IC, Puri RD, Gupta N, Kishnani PS, Mistry PK.
    Indian Pediatr; 2011 Oct 10; 48(10):779-84. PubMed ID: 22080680
    [Abstract] [Full Text] [Related]

  • 27. The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy.
    Wilson C, Spearing R, Teague L, Robertson P, Blacklock H.
    Mol Genet Metab; 2007 Oct 10; 92(1-2):131-6. PubMed ID: 17604204
    [Abstract] [Full Text] [Related]

  • 28. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
    Mazher W, Ali J, Abubakar S, Basar S, Murtaza G.
    J Ayub Med Coll Abbottabad; 2018 Oct 10; 30(3):479-481. PubMed ID: 30465391
    [Abstract] [Full Text] [Related]

  • 29. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease.
    Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, Agosti E.
    Lancet; 1994 Dec 17; 344(8938):1679-82. PubMed ID: 7996964
    [Abstract] [Full Text] [Related]

  • 30. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
    Tóth J, Szücs FZ, Benkö K, Maródi L.
    Orv Hetil; 2003 Apr 20; 144(16):749-55. PubMed ID: 12778625
    [Abstract] [Full Text] [Related]

  • 31. Individualized long-term enzyme therapy for Gaucher disease type 1 in Slovenia.
    Benedik-Dolničar M, Kitanovski L.
    Pediatr Int; 2011 Dec 20; 53(6):1018-22. PubMed ID: 21883686
    [Abstract] [Full Text] [Related]

  • 32. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study.
    Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A.
    Am J Hematol; 2013 Mar 20; 88(3):166-71. PubMed ID: 23386328
    [Abstract] [Full Text] [Related]

  • 33. First long-term results of imiglucerase therapy of type 1 Gaucher disease.
    Niederau C, vom Dahl S, Häussinger D.
    Eur J Med Res; 1998 Feb 21; 3(1-2):25-30. PubMed ID: 9512964
    [Abstract] [Full Text] [Related]

  • 34. [Gaucher's disease and enzyme replacement therapy].
    Cornu F.
    Ann Pharm Fr; 1998 Feb 21; 56(3):102-7. PubMed ID: 9770016
    [Abstract] [Full Text] [Related]

  • 35. [French results of enzyme replacement therapy in Gaucher's disease].
    Schaison G, Caubel I, Belmatoug N, Billette de Villemeur T, Saudubray JM.
    Bull Acad Natl Med; 2002 Feb 21; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
    [Abstract] [Full Text] [Related]

  • 36. [Gaucher disease type 1--therapeutic results of enzyme substitution].
    Steensberg J, Nielsen KG, Brandt NJ.
    Ugeskr Laeger; 1998 Jun 22; 160(26):3929-30. PubMed ID: 9656836
    [Abstract] [Full Text] [Related]

  • 37. A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1.
    Kishnani PS, DiRocco M, Kaplan P, Mehta A, Pastores GM, Smith SE, Puga AC, Lemay RM, Weinreb NJ.
    Mol Genet Metab; 2009 Apr 22; 96(4):164-70. PubMed ID: 19195916
    [Abstract] [Full Text] [Related]

  • 38. Plant-based oral delivery of β-glucocerebrosidase as an enzyme replacement therapy for Gaucher's disease.
    Shaaltiel Y, Gingis-Velitski S, Tzaban S, Fiks N, Tekoah Y, Aviezer D.
    Plant Biotechnol J; 2015 Oct 22; 13(8):1033-40. PubMed ID: 25828481
    [Abstract] [Full Text] [Related]

  • 39. Total glycolipid and glucosylceramide content in serum and urine of patients with Gaucher's disease type 3 before and after enzyme replacement therapy.
    Gornati R, Bembi B, Tong X, Boscolo R, Berra B.
    Clin Chim Acta; 1998 Mar 23; 271(2):151-61. PubMed ID: 9565330
    [Abstract] [Full Text] [Related]

  • 40. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 23; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.